INITIAL PUBLIC OFFERING OF EQUITY SHARES ON THE MAIN BOARD OF THE BSE LIMITED (**"BSE"**) AND "NATIONAL STOCK EXCHANGE OF INDIA LIMITED (**"NSE"**, AND TOGETHER WITH BSE, THE **"STOCK EXCHANGES"**) IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("**SEBI ICDR REGULATIONS**").

SYMBIOTEC

(Please scan this QR Code to view the Prospectus)

SYMBIOTEC PHARMALAB LIMITED

(TO BE LISTED ON THE MAIN BOARD OF BSE AND NSE)

Our Company was incorporated as 'Symbiotec Pharmalab Private Limited' as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated September 20, 2002, issued by the Registrar of Companies, Madhya Pradesh and Chhattisgarh. Subsequently, in the interest of business expansion and issuing fresh shares to the public to meet requirements of funds for a project being undertaken by the Company which would have resulted into increase in the members of the Company beyond fifty, our Company was converted from a private limited company to a public limited company, pursuant to the Board resolution dated September 22, 2005 and a resolution passed in the extraordinary general meeting of our Shareholders held on October 18, 2005 and the name of our Company was changed to Symbiotec Pharmalab Limited, and a certificate of change of name dated October 27, 2005 was issued to our Company by the Registrar of Companies, Madhya Pradesh & Chhattisgarh. Further, considering the absence of public involvement in the shareholding pattern and the management of the Company, our Company was converted to a private limited company pursuant to the Board resolution dated April 23, 2014 and a resolution passed in the extraordinary general meeting of our Shareholders on May 22, 2014 and the name of our Company was changed to Symbiotec Pharmalab Private Limited and a certificate of incorporation, consequent upon conversion to a private limited was issued by the RoC on July 25, 2014. Thereafter, as part of the Company's strategic vision for future growth and expansion, our Company was converted into a public company, pursuant to the Board resolution dated September 11, 2025 and a special resolution dated September 12, 2025 passed in the extraordinary general meeting of our Shareholders. Consequently the name of our Company was changed to Symbiotec Pharmalab Limited and a fresh certificate of incorporation dated September 26, 2025, consequent upon conversion to a public company, was issued by the Registrar of Companies, Central Processing Centre. For further details on the changes in the name and registered office of our Company, see "*History and Certain Corporate Matters*" on page 265 of the Prospectus dated August 27, 2026 ("**Prospectus**").

Corporate Identity Number: U24232MP2002PLC015293; Website: www.symbiotec.com
Registered and Corporate Office: 385/2, Pigdamber, Rau, Mhow, Indore – 453 331, Madhya Pradesh, India, **Contact Person:** Salil Jain, Company Secretary and Compliance Officer; **Telephone:** +91 731 667 6405; **Email:** secretarial@symbiotec.com

THE PROMOTERS OF OUR COMPANY: ANIL SATWANI, KASHISH SATWANI, SUSHIL SATWANI AND SATWANI HOLDINGS LLP

Our Company has filed the Prospectus with the RoC and the Equity Shares (as defined below) are proposed to be listed on the Main Board platform of the Stock Exchanges and the trading is expected to commence on Tuesday, September 1, 2026.

BASIS OF ALLOTMENT

INITIAL PUBLIC OFFERING OF 17,786,442 EQUITY SHARES OF FACE VALUE OF ₹2 EACH ("EQUITY SHARES") OF OUR COMPANY FOR CASH AT A PRICE OF ₹988.00 PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹986.00 PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING TO ₹17,570.00 MILLION^ ("OFFER"). THE OFFER COMPRISED A FRESH ISSUE OF 1,521,261 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING TO ₹1,500.00 MILLION^ BY OUR COMPANY ("FRESH ISSUE") AND AN OFFER FOR SALE OF 16,265,181 EQUITY SHARES OF FACE VALUE OF ₹2 EACH ("OFFERED SHARES") AGGREGATING ₹16,070.00 MILLION, COMPRISING OF 1,457,489 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING TO ₹1,440.00^ MILLION BY SATWANI HOLDINGS LLP (THE "PROMOTER SELLING SHAREHOLDER"), 10,000,000 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING TO ₹9,880.00 MILLION BY ROSEWOOD INVESTMENTS AND 4,807,692 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING TO ₹4,750.00 MILLION BY INDIA BUSINESS EXCELLENCE FUND – III (THE "INVESTOR SELLING SHAREHOLDERS", AND TOGETHER WITH THE PROMOTER SELLING SHAREHOLDER, THE "SELLING SHAREHOLDERS" AND SUCH OFFER FOR SALE OF EQUITY SHARES BY THE SELLING SHAREHOLDERS, THE "OFFER FOR SALE"). THE OFFER CONSTITUTED 27.68% OF THE POST-OFFER PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE OFFER INCLUDED A RESERVATION OF 33,407 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING ₹30.00 MILLION (CONSTITUTING 0.05% OF THE POST OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY), FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER CONSTITUTED 27.68% AND 27.63%, RESPECTIVELY, OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. OUR COMPANY, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS, OFFERED A DISCOUNT OF 9.11% (EQUIVALENT TO ₹90.00 PER EQUITY SHARE) TO THE OFFER PRICE TO ELIGIBLE EMPLOYEES BIDDING UNDER THE EMPLOYEE RESERVATION PORTION ("EMPLOYEE DISCOUNT").

^A discount of ₹90.00 per Equity Share was offered to Eligible Employees bidding in the Employee Reservation Portion.

ANCHOR INVESTOR OFFER PRICE: ₹988.00 PER EQUITY SHARE OF FACE VALUE OF ₹2 EACH

OFFER PRICE: ₹988.00 PER EQUITY SHARE OF FACE VALUE OF ₹2 EACH

THE OFFER PRICE IS 494.00 TIMES THE FACE VALUE OF THE EQUITY SHARES OF ₹2 EACH

RISK TO INVESTORS | *FOR DETAILS, REFER TO THE SECTION TITLED "RISK FACTORS" ON PAGE 28 OF THE PROSPECTUS.*

1) **Revenue dependence on sale of Active Pharmaceutical Ingredients ("APIs"):**
We derive almost all of our revenue from the sale of API products, including corticosteroid and steroidal-hormones. In addition to manufacturing API products that we sell, we offer our services as a contract development and manufacturing organisation ("CDMO") for specialty pharmaceutical and nutraceutical companies. Any reduction in demand for API products, and our top products in particular, or a temporary or permanent discontinuation in our manufacturing operations for such products, could have an adverse effect on our business, results of operations, financial condition and cash flows.

Particulars	Fiscal 2026		Fiscal 2025		Fiscal 2024	
	Amount (₹ million)	Percentage of revenue from operations (%)	Amount (₹ million)	Percentage of revenue from operations (%)	Amount (₹ million)	Percentage of revenue from operations (%)
Sale of APIs (A)	8,350.05	96.07%	7,447.54	99.10%	7,162.47	100.00%
Sale of complex injectables (B)	330.50	3.80%	-	-	-	-
CDMO services (C)	10.94	0.13%	68.00	0.90%	-	-
Total (A+B+C)	**8,691.49**	**100.00%**	**7,515.54**	**100.00%**	**7,162.47**	**100.00%**

2) **Audit and inspections risk:** We operate in a highly competitive industry where regulatory standards are not only extensive but also continuously evolving. We are required to comply with regulations and quality standards stipulated by regulatory authorities and certain of our customers. Our manufacturing facilities and products are subject to periodic inspections and audits by these regulatory authorities and customers. If we are not in compliance with the requirements prescribed by such authorities or terms stipulated in contracts with our customers, we may be subject to regulatory actions, including issuance of warning letters, imposition of sanctions, amendment or withdrawal of our existing approvals, product seizure, interruption of our operations, or claims resulting from non-compliance with contractual obligations.

3) **Dependence on export markets:** As of March 31, 2026, revenue from external customers outside India contributed 67.04%, 55.19% and 59.97% of our revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Our inability to handle risks associated with our export sales could adversely affect our sales to customers in foreign countries, our results of operations, financial condition and cash flows.

Particulars	Fiscal 2026		Fiscal 2025		Fiscal 2024	
	Amount (₹ million)	Percentage of revenue from operations (%)	Amount (₹ million)	Percentage of revenue from operations (%)	Amount (₹ million)	Percentage of revenue from operations (%)
Revenue from external customers - India (A)	2,865.05	32.96%	3,367.75	44.81%	2,867.23	40.03%
Revenue from external customers outside India (B)	5,826.44	67.04%	4,147.79	55.19%	4,295.24	59.97%
- Europe	2,529.86	29.11%	2,271.07	30.22%	2124.20	29.66%
- United States	1,140.00	13.12%	302.02	4.02%	642.60	8.97%
- China	82.90	0.95%	115.58	1.54%	22.19	0.31%
- Rest of the world*	2,073.68	23.86%	1,459.13	19.41%	1506.25	21.03%
Revenue from operations (A+B)	**8691.49**	**100.00%**	**7515.54**	**100.00%**	**7162.47**	**100.00%**

** Rest of the world includes Asia (other than India and China) and Africa.*

4) **Tariff and anti-sourcing risk:** Revenue from the United States represented 13.12%, 4.02% and 8.97% of our revenue from operations for Fiscals 2026, 2025 and 2024. The imposition of tariffs or other anti-sourcing measures by the United States could increase our costs, affect the competitiveness of our products and adversely affect our business, results of operations, financial condition and cash flows.

5) **Customer concentration risk:** We derive a substantial portion of our revenue from certain key customers, with our top ten customers accounting for 57.59%, 55.90% and 61.65% of our revenue from sale of products in Fiscals 2026,2025 and 2024, respectively. Any loss of, or reduction in orders from, these customers could adversely affect our business, results of operations, financial condition and cash flows.

Particulars	Fiscal 2026		Fiscal 2025		Fiscal 2024	
	Amount (₹ million)	Percentage of revenue from sale of products (%)	Amount (₹ million)	Percentage of revenue from sale of products (%)	Amount (₹ million)	Percentage of revenue from sale of products (%)
Top five customers	3,475.98	43.01%	3,037.13	42.27%	3,154.83	48.51%
Top ten customers	4,654.71	57.59%	4,015.76	55.90%	4,009.50	61.65%

6) **Geographic concentration risk:** As of March 31, 2026, we operated the Rau Facility and the Pithampur Facility in the state of Madhya Pradesh in India. In addition, our Ujjain Facility and our Mhow Facility, which we have commissioned and where we have started R&D and pilot-scale operations as of March 31, 2026, are also located in Madhya Pradesh. Any adverse developments affecting Madhya Pradesh or its surrounding regions could adversely affect our business, results of operations, financial condition and cash flows. A slowdown, interruption or shutdown in our manufacturing operations could have an adverse effect on our business, results of operations, financial condition and cash flows.

7) **Supplier concentration risk:** We depend on certain suppliers for raw materials for our operations. Purchases from our top ten suppliers accounted for 25.50%, 18.41% and 50.33% of our total expenses in Fiscals 2026, 2025 and 2024, respectively. Any loss of such suppliers or non-performance of their obligations could adversely affect our business, results of operations, financial condition and cash flows.

Particulars	Fiscal 2026		Fiscal 2025		Fiscal 2024	
	Amount (₹ million)	Percentage of total expenses (%)	Amount (₹ million)	Percentage of total expenses (%)	Amount (₹ million)	Percentage of total expenses (%)
Top five suppliers	1,501.96	21.16%	850.41	13.97%	2,293.90	38.81%
Top ten suppliers	1,810.15	25.50%	1,120.78	18.41%	2,974.31	50.33%

8) **Competition risk:** We operate in a highly competitive market. We face competition both within our API manufacturing business and in our role as a CDMO, which we have recently commenced. An inability to compete effectively may adversely affect our business, results of operations, financial condition and cash flows.

9) **Dependence on imported raw materials:** We procure a portion of our raw material requirements from different countries, including China and the United States. Any adverse developments in these countries, or the laws governing our imports from these countries, could disrupt our raw material supply and adversely affect our results of operations, financial condition and cash flows

Particulars	Fiscal 2026		Fiscal 2025		Fiscal 2024	
	Amount (₹ million)	Percentage of total expenses (%)	Amount (₹ million)	Percentage of total expenses (%)	Amount (₹ million)	Percentage of total expenses (%)
Raw materials sourced domestically	**781.35**	**11.00%**	**915.79**	**15.04%**	**785.62**	**12.84%**
Raw material imports	**1,868.82**	**26.32%**	**1,197.36**	**19.67%**	**3,275.61**	**55.43%**
- United States of America	59.77	0.84%	39.10	0.64%	20.02	0.34%
- China	1,695.24	23.88%	1,024.32	16.82%	3,119.82	52.79%
- Other countries*	113.81	1.60%	133.94	2.20%	135.76	2.30%

**Other countries include countries such as Singapore, Malaysia and Germany.*

10) **Product development risk:** Our success depends on our ability to develop and commercialise new products in a timely manner. Our research and development ("R&D") efforts are central to our ability to build, scale, and sustain complex manufacturing technologies across platforms. If our research and development efforts do not succeed, or the products we commercialise do not perform as expected, the introduction of new products may be hindered, which could adversely affect our business, results of operations, financial condition and cash flows. In order to remain competitive, we must develop, test and manufacture new products, which must meet regulatory standards and receive requisite regulatory approvals.

Particulars	Fiscal 2026	Fiscal 2025	Fiscal 2024
Research and development expenses (₹ million) (A)	296.95	311.43	205.09
Total expenses (₹ million) (B)	7,099.02	6,088.49	5,909.85
Research and development expenses, as a percentage of total expenses (%) (A/B*100)	4.18%	5.12%	3.47%

11) **Risk related to transfer of shares:** The Investor Selling Shareholders, India Business Excellence Fund – III, together with its co-investors, namely, Mahendra Fulchand Sundesha and Narnarayan Nathmal Saraf jointly with Indra Saraf have transferred an aggregate of 203,866 Equity Shares of face value of ₹2 each for a consideration of ₹200.00 per Equity Share aggregating to ₹40.77 million and Rosewood Investments has transferred 1,508,478 Equity Shares of face value of ₹2 each for a consideration of ₹200.00 per Equity Share aggregating to ₹301.69 million, to our Promoter, Satwani Holdings LLP pursuant to the upside sharing arrangement as provided for in the Investment Agreement which may have been transferred at a price lower than the Offer Price and has resulted in an increase in the pre-offer shareholding of our Promoter of Satwani Holdings LLP.

12) **The Selling Shareholders will receive the entire proceeds from the Offer for Sale. We will not receive or benefit from any proceeds from the Offer for Sale portion.**

13) **The weighted average cost of acquisition per Equity Share acquired by our Promoters (which includes the Promoter Selling Shareholder) and Selling Shareholders, as on the date of the Prospectus is as follows:**

S. No.	Name of Promoter	Number of Equity Shares of face value of ₹ 2 each held as on date	WACA per Equity Share (in ₹)	Number of Equity Shares of face value of ₹ 2 each acquired in last one year	WACA of Equity Shares acquired in last one year
Promoters					
1	Anil Satwani	2,810,896	276.00	3,120,000	276.00
2	Kashish Satwani	2,750,896	273.04	27,00,000	276.00
3	Sushil Satwani	1,233,938	72.37	313,938	276.00
4	Satwani Holdings LLP^	11,277,374	49.43	2,227,734	217.58
Selling Shareholders					
1	Rosewood Investments	19,042,092	147.21	NA	NA
2	India Business Excellence Fund - III	11,386,687	147.21	NA	NA

As certified by M/s. A B M S & Associates, Chartered Accountants by way of their certificate dated August 27, 2026.

^ Also participating as the Promoter Selling Shareholder.

14) **Weighted Average Return on Net worth for past three Fiscals i.e. 2026, 2025 and 2024 is 10.99%**

15) **Weighted average cost of acquisition of all equity shares transacted in the one year, 18 months and three years preceding the date of the Prospectus**

Period	Weighted average cost of acquisition per equity share (in ₹)^	Cap Price is 'x' times the weighted average cost of acquisition	Range of acquisition price per equity share: lowest price – highest price (in ₹)^#
Last one year preceding the date of the Prospectus	440.00	2.25	0-988.00
Last 18 months preceding the date of the Prospectus	432.98	2.28	0-988.00
Last three years preceding the date of the Prospectus	432.98	2.28	0-988.00

^As certified by M/s. A B M S & Associates, Chartered Accountants by way of their certificate dated August 27, 2026.

 # Adjusted for sub-division of equity shares.

16) **The details of the Price/Earnings (P/E), Earnings per Share (EPS), Return on Net Worth (RoNW) and Net Asset Value (NAV) per Equity Share for our Company and peer group for the year ended 2026 appear hereunder:**

Name of the company	Face value (₹ per equity share)	Closing price on August 25, 2026 (₹)	Revenue from operations for Fiscal 2026 (in ₹ million)	EPS (₹) for Fiscal 2026		NAV (₹ per equity share) for Fiscal 2026	P/E ratio as on August 25, 2026	RoNW for Fiscal 2026 (%)
				Basic	Diluted			
Symbiotec Pharmalab Limited	2	N. A	8,691.49	19.10	19.00	184.69	N. A	9.48
Listed Peers								
Concord Biotech Limited	1	1,548.00	10,549.00	24.78	24.78	NA	62.47	14.00
Divi's Laboratories Limited	2	8,744.50	105,600.00	96.75	96.75	631.00	90.38	16.50
Cohance Lifesciences Limited	1	445.40	22,685.50	4.69	4.68	NA	95.17	7.00
Laurus Labs Limited	2	1,866.20	68,129.00	16.47	16.45	NA	113.45	16.80

**As certified by M/s. A B M S & Associates, Chartered Accountants, pursuant to certificate dated August 27, 2026.*

For further details and relevant footnotes, please refer to page 150 of the Prospectus.

17) **The BRLMs associated with the Offer have handled 87 public issues in the past three years, out of which 26 issues closed below the offer price on listing date.**

Name of BRLMs	Total Issues	Issues closed below IPO price on listing date
JM Financial Limited*	34	11
Avendus Capital Private Limited*	4	1
Motilal Oswal Investment Advisors Limited^^*	25	8
Nomura Financial Advisory and Securities (India) Private Limited*	8	2
Common issues handled by the BRLMs	16	4
Total	**87**	**26**

^^In compliance with the proviso to regulation 21A(1) and explanation (iii) to regulation 21A(1) of the SEBI Merchant Bankers Regulations, and regulation 23(3) of the SEBI ICDR Regulations, Motilal Oswal Investment Advisors Limited will be involved only in marketing the Offer. Motilal Oswal Investment Advisors Limited has signed the due diligence certificate and has been disclosed as a BRLM for the Offer.

**Issues handled where there were no common BRLMs.*

Continued on next page...

...continued from previous page.

BID/OFFER PERIOD

ANCHOR INVESTOR BIDDING DATE OPENED AND CLOSED ON FRIDAY, AUGUST 21, 2026

BID/OFFER OPENED ON MONDAY, AUGUST 24, 2026

BID/OFFER CLOSED ON THURSDAY, AUGUST 27, 2026

This Offer was being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contract (Regulation) Rules, 1957 ("**SCRR**") read with Regulation 31 of the SEBI ICDR Regulations and in compliance with Regulation 6(1) of the SEBI ICDR Regulations wherein not more than 50% of the Net Offer was available for allocation on a proportionate basis to Qualified Institutional Buyers ("**QIBs**", and such portion, the "**QIB Portion**"), provided that our Company, in consultation with the BRLMs, allocated 60% of the QIB Portion to Anchor Investors on a discretionary basis ("**Anchor Investor Portion**"). 40% of the Anchor Investor Portion was reserved as under: (i) 33.33% for the domestic Mutual Funds; and (ii) 6.67% for Life Insurance Companies and Pension Funds, subject to valid Bids having been received from the domestic Mutual Funds, Life Insurance Companies and Pension Funds at or above the price at which allocation was made to Anchor Investors ("**Anchor Investor Allocation Price**") in accordance with the SEBI ICDR Regulations. Any under-subscription in the reserved category specified in clause (ii) above would have been allocated to domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares would have been added to the QIB Portion (other than the Anchor Investor Portion) (the "**Net QIB Portion**"). Further, 5% of the Net QIB Portion was available for allocation on a proportionate basis to Mutual Funds only, subject to valid Bids having been received at or above the Offer Price, and the remainder of the Net QIB Portion was available for allocation on a proportionate basis to QIB Bidders (other than Anchor Investors) including Mutual Funds subject to valid Bids having been received at or above the Offer Price. However, if the aggregate demand from Mutual Funds was less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion were added to the remaining Net QIB Portion for proportionate allocation to all QIBs. Further, not less than 15% of the Net Offer was available for allocation to Non-Institutional Bidders (out of which one-third of the portion available to Non-Institutional Bidders was reserved for Bidders with an application size of more than ₹0.20 million and up to ₹1.00 million and two-thirds was reserved for Bidders with an application size of more than ₹1.00 million, provided that the unsubscribed portion in either of the aforementioned sub-categories would have been allocated to Bidders in the other sub-category) and not less than 35% of the Net Offer was available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids having been received from them at or above the Offer Price. Further, Equity Shares was allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price. All Bidders, other than Anchor Investors, were required to participate in the Offer by mandatorily utilising the Application Supported by Blocked Amount ("**ASBA**") process by providing details of their respective ASBA Account (as defined hereinafter) and UPI ID in case of UPI Bidders (as defined hereinafter), as applicable, pursuant to which their corresponding Bid Amounts were blocked by the SCSBs or by the Sponsor Banks under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors were not permitted to participate in the Offer through the ASBA process. For further details, see "*Offer Procedure*" on page 451of the Prospectus.

The Company received 34 Anchor Investor Application Forms from 26 Anchor Investors (including 11 domestic mutual funds through 19 Mutual Fund schemes) for 54,96,165 Equity Shares. Such 26 Anchor Investors through 34 Anchor Investor Application Forms were allocated 53,25,909 Equity Shares at a price of ₹988/- per Equity Share under the Anchor Investor Portion, aggregating to ₹5,26,19,98,092.00/-.

The Offer received 5,320,223 applications for 941,418,330 Equity Shares (prior to rejections) resulting in 52.93 times subscription as disclosed in the Prospectus. The details of the applications received in the Offer from various categories are as under (before rejections):

Sr. No	Category	No. of Applications received*	No. of Equity Shares applied	No. of Equity Shares reserved as per Prospectus	No. of times Subscribed	Amount (₹)
A	Eligible Employees	24,242	537,090	33,407	16.08	482,057,805.00
B	Retail Individual Investors	4,905,126	85,450,110	6,213,563	13.75	84,424,592,850.00
C	Qualified Institutional Bidders (excluding Anchor Investors)	226	642,133,275	3,550,607	180.85	634,427,675,700.00
D	Non Institutional Investors -More than 0.2 Million Upto 1 Million	239,669	51,987,180	887,652	58.57	51,362,641,215.00
E	Non Institutional Investors -Above 1 Million	150,926	155,814,510	1,775,304	87.77	153,943,900,635.00
F	Anchor Investors	34	5,496,165	5,325,909	1.03	5,430,211,020.00
	Total	**5,320,223**	**941,418,330**	**17,786,442**	**52.93**	**930,071,079,225.00**

*This includes 17,092 applications for 2,97,990 Equity Shares from Retail Individual Investors Category which were not in book but excludes bids (UPI Mandates) not accepted by investors..

Final Demand

A summary of the final demand as per BSE and NSE as on the Bid/Offer Closing Date at different Bid prices is as under:

Sr. No .	Bid Price	No. of Equity Shares	% to Total	Cumulative Total	Cumulative % of Total
1	938	134,145	0.01	134,145	0.01
2	939	2,340	0.00	136,485	0.01
3	940	17,250	0.00	153,735	0.02
4	941	570	0.00	154,305	0.02
5	942	930	0.00	155,235	0.02
6	943	600	0.00	155,835	0.02
7	944	165	0.00	156,000	0.02
8	945	4,875	0.00	160,875	0.02
9	946	540	0.00	161,415	0.02
10	947	675	0.00	162,090	0.02
11	948	4,095	0.00	166,185	0.02
12	949	480	0.00	166,665	0.02
13	950	32,295	0.00	198,960	0.02
14	951	1,260	0.00	200,220	0.02
15	952	705	0.00	200,925	0.02
16	953	1,095	0.00	202,020	0.02
17	954	735	0.00	202,755	0.02
18	955	30,435	0.00	233,190	0.02
19	956	795	0.00	233,985	0.02
20	957	900	0.00	234,885	0.02
21	958	12,930	0.00	247,815	0.03
22	959	1,200	0.00	249,015	0.03
23	960	8,415	0.00	257,430	0.03
24	961	165	0.00	257,595	0.03
25	962	240	0.00	257,835	0.03
26	963	5,505	0.00	263,340	0.03
27	964	1,290	0.00	264,630	0.03
28	965	3,765	0.00	268,395	0.03
29	966	18,105	0.00	286,500	0.03
30	967	1,440	0.00	287,940	0.03
31	968	12,225	0.00	300,165	0.03
32	969	2,340	0.00	302,505	0.03
33	970	6,150	0.00	308,655	0.03
34	971	1,590	0.00	310,245	0.03
35	972	240	0.00	310,485	0.03
36	973	435	0.00	310,920	0.03
37	974	1,755	0.00	312,675	0.03
38	975	7,380	0.00	320,055	0.03
39	976	585	0.00	320,640	0.03
40	977	3,600	0.00	324,240	0.03
41	978	3,885	0.00	328,125	0.03
42	979	1,260	0.00	329,385	0.03
43	980	23,280	0.00	352,665	0.04
44	981	5,640	0.00	358,305	0.04
45	982	2,415	0.00	360,720	0.04
46	983	6,840	0.00	367,560	0.04
47	984	7,515	0.00	375,075	0.04
48	985	18,165	0.00	393,240	0.04
49	986	67,290	0.01	460,530	0.05
50	987	91,290	0.01	551,820	0.06
51	988	867,498,450	91.55	868,050,270	91.61
52	**CUT-OFF**	**79,530,795**	**8.39**	**947,581,065**	**100.00**
	TOTAL	**947,581,065**	**100.00**		

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being BSE on Friday, August 28, 2026.

A. Allotment to Eligible Employees (Up to ₹2,00,000/-) (after rejections) (including ASBA Applications)

The Basis of Allotment to the Eligible Employees, who have bid at the Offer Price ₹898 per Equity share (Net of Employee Discount i.e. ₹90 per equity share), was finalized in consultation with the BSE. This category has been subscribed to the extent of 1.86 (after rejections) times. The total number of Equity Shares Allotted in this category is 33,407 Equity Shares to 528 successful Eligible Employees. The category-wise details of the Basis of Allotment are as under: (Sample)

SR. NO .	CATEGORY	NO. OF APPLICATIONS RECEIVED	% OF TOTAL	TOTAL NO. OF EQUITY SHARES APPLIED	% TO TOTAL	NO. OF EQUITY SHARES ALLOTTED PER APPLICANT	RATIO	TOTAL NO. OF EQUITY SHARES ALLOTTED
1	15	138	23.96	2,070	4.06	15	90:138	1,350
2	30	101	17.53	3,030	5.94	20	1:1	2,020
3	45	54	9.38	2,430	4.77	30	1:1	1,620
4	60	29	5.03	1,740	3.41	39	1:1	1,131
5	75	26	4.51	1,950	3.83	49	1:1	1,274
6	90	16	2.78	1,440	2.83	59	1:1	944
7	105	23	3.99	2,415	4.74	69	1:1	1,587
8	120	14	2.43	1,680	3.30	79	1:1	1,106
10	150	20	3.47	3,000	5.89	98	1:1	1,960
11	165	6	1.04	990	1.94	108	1:1	648
12	180	4	0.69	720	1.41	118	1:1	472
17	255	6	1.04	1,260	2.47	137	1:1	822
18	285	2	0.35	420	0.82	137	1:1	274
20	330	2	0.35	420	0.82	137	1:1	274
21	345	2	0.35	420	0.82	137	1:1	274
22	360	1	0.17	210	0.41	137	1:1	137
23	375	1	0.17	210	0.41	137	1:1	137
24	390	1	0.17	210	0.41	137	1:1	137
29	480	1	0.17	210	0.41	137	1:1	137
30	495	4	0.69	840	1.65	137	1:1	548
31	510	1	0.17	210	0.41	137	1:1	137
32	525	1	0.17	210	0.41	137	1:1	137
33	540	1	0.17	210	0.41	137	1:1	137
34	555	15	2.60	3,150	6.18	137	1:1	2,055
35	0	All applicants from Serial no 14 to 34 for Additional 1(one) share				1	21:114	21
	TOTAL	**576**	**100.00**	**50,970**	**100.00**			**33,407**

B. Allotment to Retail Individual Investors (after rejections) (including ASBA Applications)

The Basis of Allotment to the Retail Individual Investors, who have bid at the Cut-Off Price or at the Offer Price of ₹988 per Equity Share, was finalized in consultation with BSE. This category has been subscribed to the extent of 13.42 times (after rejections). The total number of Equity Shares Allotted in Retail Portion is 62,13,563 Equity Shares to 4,14,237 successful Retail Individual Investors. The category-wise details of the Basis of Allotment are as under:

Sl no	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted
1	15	4,528,349	94.60	67,925,235	81.47	15	9:104	5,878,125
2	30	132,239	2.76	3,967,170	4.76	15	9:104	171,660
3	45	43,801	0.92	1,971,045	2.36	15	9:104	56,850
4	60	20,032	0.42	1,201,920	1.44	15	9:104	26,010
5	75	14,694	0.31	1,102,050	1.32	15	9:104	19,080
6	90	7,748	0.16	697,320	0.84	15	9:104	10,065
8	120	2,302	0.05	276,240	0.33	15	9:104	2,985
9	135	1,575	0.03	212,625	0.26	15	9:104	2,040
10	150	5,017	0.10	752,550	0.90	15	9:104	6,510
11	165	1,030	0.02	169,950	0.20	15	9:104	1,335
12	180	1,364	0.03	245,520	0.29	15	9:104	1,770
13	195	20,516	0.43	4,000,620	4.80	15	9:104	26,625
14	0	22362 Allottees from Serial no 2 to 13 Additional 1(one) share				1	8:22362	8
	TOTAL	**4,786,759**	**100.00**	**83,371,905**	**100.00**			**6,213,563**

C. Allotment to Non-Institutional Investors (More than ₹200,000 and up to ₹1,000,000) (after rejections)

The Basis of Allotment to the Non-Institutional Investors (More than ₹200,000 and up to ₹1,000,000), who have bid at the Offer Price of ₹988 per Equity Share was finalized in consultation with BSE. The sub-category of the Non-Institutional Portion comprising Non-Institutional Investors Bidding (More than ₹200,000 and up to ₹1,000,000) has been subscribed to the extent of 57.63 times (after rejections). The total number of Equity Shares Allotted in this category is 8,87,652 Equity Shares to 4,226 successful Non- Institutional Investors. The category-wise details of the Basis of Allotment are as under: (Sample)

Sr no	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares allotted per applicant	Ratio	Total No. of Equity Shares allotted
1	210	225,770	95.67	47,411,700	92.69	210	17:949	849,240
2	225	3,511	1.49	789,975	1.54	210	63:3511	13,230
14	405	168	0.07	68,040	0.13	210	3:168	630
20	510	302	0.13	154,020	0.30	210	5:302	1,050
28	990	32	0.01	31,680	0.06	210	1:32	210
29	1,005	392	0.17	393,960	0.77	210	7:392	1,470
30	435	27	0.01	11,745	0.02	210	0:27	0
31	555	21	0.01	11,655	0.02	210	0:21	0
44	810	23	0.01	18,630	0.04	210	0:23	0
51	930	4	0.00	3,720	0.01	210	0:4	0
52	945	6	0.00	5,670	0.01	210	0:6	0
53	960	5	0.00	4,800	0.01	210	0:5	0
54	975	15	0.01	14,625	0.03	210	0:15	0
55	0	All applicants from Serial no 30 to 54 for 1 (one) lot of 210 shares				210	1:300	210
56	0	182 Allottees from Serial no 2 to 55 Additional 1 (One) share				1	1:1	182
57	0	182 Allottees from Serial no 2 to 55 Additional 1(one) share				1	10:182	10
	TOTAL	**235,996**	**100.00**	**51,151,095**	**100.00**			**8,87,652**

D. Allotment to Non-Institutional Investors (More than ₹ 1,000,000)

The Basis of Allotment to the Non-Institutional Investors (More than ₹1,000,000), who have bid at the Offer Price of ₹988 Equity Share was finalized in consultation with the BSE. The sub-category of the Non-Institutional Portion comprising Non-Institutional Investors Bidding above ₹1,000,000 has been subscribed to the extent of 87.02 times (after rejections). The total number of Equity Shares Allotted in this category is 1,775,304 Equity Shares to 8,453 successful applicants Non-Institutional Investors. The category-wise details of the Basis of Allotment are as under (Sample):

Sr no.	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares allotted per applicant	Ratio	Total No. of Equity Shares allotted
1	1,020	144,566	96.61	147,457,320	95.45	210	10:177	1,715,070
2	1,035	1,446	0.97	1,496,610	0.97	210	82:1446	17,220
3	1,050	1,191	0.80	1,250,550	0.81	210	67:1191	14,070
30	1,620	10	0.01	16,200	0.01	210	1:10	210
31	1,635	36	0.02	58,860	0.04	210	2:36	420
121	3,600	1	0.00	3,600	0.00	210	0:1	0
135	4,500	5	0.00	22,500	0.01	210	0:5	0
151	6,075	1	0.00	6,075	0.00	210	0:1	0
177	25,305	2	0.00	50,610	0.03	210	0:2	0
178	30,300	1	0.00	30,300	0.02	210	0:1	0
179	30,360	2	0.00	60,720	0.04	210	0:2	0
180	45,000	1	0.00	45,000	0.03	210	0:1	0
181	60,735	1	0.00	60,735	0.04	210	0:1	0
182	132,000	1	0.00	132,000	0.09	210	0:1	0
183	0	All applicants from Serial no 45 to 182 for 1 (one) lot of 210 shares				210	8:286	1,680
184	0	8,453 Allottees from Serial no 1 to 183 Additional 1(one) share				1	7:340	174
	TOTAL	**149,636**	**100.00**	**154,487,460**	**100.00**			**1,775,304**

E. Allotment to QIBs (Excluding Anchor Investors) (after rejections)

Allotment to QIBs (excluding Anchor Investors), who have Bid at the Offer Price of ₹988 per Equity Share has been done on a proportionate basis in consultation with BSE. This category has been subscribed to the extent of 180.85 times of Net QIB Portion. As per the SEBI ICDR Regulations, Mutual Funds were Allotted 5% of the Equity Shares of Net QIB Portion available i.e. 177,530 Equity Shares and other QIBs including Mutual Funds were Allotted the remaining available Equity Shares i.e. 3,373,077 Equity Shares on a proportionate basis. The total number of Equity Shares Allotted in the Net QIB Portion is 3,550,607 Equity Shares, which were allotted to 226 successful QIB Bidders. The category- wise details of the Basis of Allotment are as under.

Category	FI'S/BANK'S	MF'S	IC'S	NBFC'S	AIF	FPC/FII	OTH	Total
ALLOTMENT	1,730,057	360,407	173,695	474,840	149,941	661,667	-	**3,550,607**

F. Allotment to Anchor Investors

The Company, in consultation with the BRLM has allotted 53,25,909 Equity Shares to 26 Anchor Investors (through 34 Anchor Investor Application Forms, including 11 domestic Mutual Funds through 19 Mutual Fund schemes) at an Anchor Investor Offer Price of ₹988.00 per Equity Share in accordance with the SEBI ICDR Regulations. This represents 60% of total QIB portion.

Category	FI'S/BANK'S	MF'S	IC'S	NBFC'S	AIF	FPC/FII	OTH	Total
ALLOTMENT	-	3,198,480	513,461	253,050	303,660	1,057,258	-	**5,325,909**

The Board of Directors in their meeting held on August 28, 2026 has taken on record the Basis of Allotment of Equity Shares approved by the Designated Stock Exchange, being BSE and resolution approving the Basis of Allotment was passed on August 28, 2026. The Allotment Advice-cum-Unblocking intimations have been dispatched to the email id of the Investors as registered with the Depositories. Further, the instructions to the Self Certified Syndicate Banks for unblocking of funds, transfer to Public Offer Account have been issued on August 28, 2026 and payments to non-Syndicate brokers have been issued on August 29, 2026. In case the same is not received within ten days, investors may contact the Registrar to the Offer at the address given below. The Equity Shares Allotted to the successful Allottees have been uploaded on August 31, 2026 for credit into the respective beneficiary accounts subject to validation of the account details with the Depositories concerned. The Company filed the listing applications with each NSE and BSE on August 31, 2026. The Company has received listing and trading approvals from NSE and BSE and the trading will commence on Tuesday, September 1, 2026.

Note: All capitalised terms used and not specifically defined herein shall have the same meaning as ascribed to them in the Prospectus.

INVESTORS PLEASE NOTE

The details of the Allotment made will be hosted on the website of the Registrar to the Offer, MUFG Intime India Private Limited (*Formerly Link Intime India Private Limited*) at www.in.mpms.mufg.com.

All future correspondence in this regard may kindly be addressed to the Registrar to the Offer quoting full name of the First/Sole Bidder, Bid cum Application Form number, Bidder DP ID, Client ID, PAN, date of submission of Bid cum Application Form, address of the Bidder, number of Equity Shares applied for, the name and address of the Designated Intermediary where the Bid cum Application Form was submitted by the Bidder and a copy of the Acknowledgment Slip received from the Designated Intermediary at the address given below:

MUFG MUFG Intime

MUFG Intime India Private Limited
(*Formerly Link Intime India Private Limited*)
C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai 400 083, Maharashtra, India
Telephone: +91 810 811 4949
Email: symbiotecpharmalab.ipo@in.mpms.mufg.com
Investor grievance email: symbiotecpharmalab.ipo@in.mpms.mufg.com
Website: www.in.mpms.mufg.com
Contact person: Shanti Gopalkrishnan
SEBI Registration No: INR000004058

For **Symbiotec Pharmalab Limited**
On behalf of the Board of Directors
Sd/-
Salil Jain
Company Secretary and Compliance Officer

Place: Madhya Pradesh, India
Date: August 31, 2026

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF SYMBIOTEC PHARMALAB LIMITED.

Symbiotec Pharmalab Limited filed a Prospectus dated August 27, 2026 with RoC and the stock exchanges. The Prospectus is available on the website of the Company at www.symbiotec.com, SEBI at www.sebi.gov.in, as well as on the websites of the BRLMs, i.e. JM Financial Limited at www.jmfl.com, Avendus Capital Private Limited at www.avendus.com, Motilal Oswal Investment Advisors Limited at www.motilaloswal.com and Nomura Financial Advisory and Securities (India) Private Limited at www.nomuraholdings.com/company/group/asia/india/index.html, respectively and the websites of National Stock Exchange of India Limited and BSE Limited at www.nseindia.com and www.bseindia.com, respectively. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, please see "***Risk Factors***" on page 28 of the Prospectus.

This announcement does not constitute an invitation or offer of securities for sale in any jurisdiction.

The Equity Shares offered in the Offer have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended ("**U.S. Securities Act**") or any other applicable law of the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold outside of the United States in "offshore transactions" as defined in and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdictions where such offers and sales are made.